Eli Lilly said on Friday it expects 2013 earnings to increase to $3.75 to $3.90 per share excluding items.
As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.
It's hard to see how lawmakers can avoid touching health insurance if they want to eliminate loopholes and curtail deductions so as to raise revenue and lower tax rates.
Wondering how the market will first react, if and when we go over the fiscal cliff? Cramer thinks we may have just gotten an early glimpse.
Drug maker Baxter International said it will buy privately held Swedish company Gambro for about $2.76 billion to broaden its dialysis product portfolio.
Johnson & Johnson announced on Friday that it had elected a new chairman, with its current chair planning to step down within a month and retire shortly thereafter.
TheStreet.com details the 10 best-performing biopharmaceutical stocks of 2012 and their outlook for 2013.
Four factors will continue to drag on the economy for 2013, Blackstone Advisory Partners Vice Chairman Byron Wien said Wednesday on CNBC.
Three of the top ten dividend stocks in the S&P are drug stocks. Will they lose out if dividend taxes rise?
From rural ambulance squads to prestigious hospitals, health care workers are struggling to keep vital medicines in stock because of a drug shortage crisis that is proving to be stubbornly difficult to fix, the New York Times reports.
Marijn Dekkers, CEO of Bayer, explains to CNBC that while Bayer has felt increased pressure on drug pricing from governments, its success in research and development has the company positioned for success.
Following President Barack Obama’s re-election, three investment sectors are worth playing via exchange-traded funds, Tom Lydon of Global Trends Investments said Thursday on CNBC.
Jim Cramer explains why CVS Caremark is ready to "declare victory" in the pharmacy wars.
CVS Caremark posted higher quarterly earnings on Tuesday and raised its guidance for the full year, citing higher drugstore chain sales and an increase in pharmacy benefit clients.
Pfizer reported quarterly earnings on Thursday that was largely in line with analysts' forecasts, but revenue fell short following the loss of patent protection on its blockbuster Lipitor cholesterol fighter.
Christopher Viehbacher, CEO, Sanofi says that as cost rises, the firm is growing its emerging-markets business outside of the BRIC nations.
Merck reported higher-than-expected quarterly results on Friday and said it continued to expect full-year revenue to be at or near 2011 levels on a constant currency basis.
For traders looking to get long J&J, but who do not want to chase the stock, this is a good alternative that can make money in an up, sideways, or modestly down market.
A new cancer drug being trialed by Swiss Drugmaker Roche Holding will present a key opportunity for the company in the coming months, Roche CEO Severin Schwan told CNBC Tuesday.
Johnson & Johnson reported better-than-expected quarterly results on Tuesday, as prescription drug sales rebounded with the help of newer products and jitters about medical device sales proved unfounded.